Key terms

About GLYC

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest GLYC news

Today 8:20am ET Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC) Yesterday 9:25pm ET Positive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth Initiatives Yesterday 12:35pm ET Buy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong Pipeline Yesterday 12:30pm ET Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX) Yesterday 11:35am ET Buy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of Uproleselan Yesterday 7:15am ET GlycoMimetics reports Q4 EPS (14c), consensus (15c) Mar 25 8:00am ET Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024 Mar 01 9:32am ET GlycoMimetics Provides Update with Investor Presentation Feb 22 7:46am ET Promising Outlook for GlycoMimetics’ Uproleselan in AML Treatment: A Buy Rating with Adjusted Price Target Jan 26 11:25am ET Biotech Alert: Searches spiking for these stocks today Jan 05 11:06am ET GlycoMimetics data reaffirm Sickle Cell opportunity, says Capital One Jan 04 7:12am ET GlycoMimetics announces GMI-1687 trial met primary, secondary endpoints Jan 03 9:26am ET Buy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for Uproleselan Jan 03 7:06am ET Apollomics completes enrollment in Phase 3 bridging study of APL-106 Jan 02 4:41pm ET GlycoMimetics in manufacturing pact with Thermo Fisher for uproleselan

No recent news articles are available for GLYC

No recent press releases are available for GLYC

GLYC Financials

1-year income & revenue

Key terms

GLYC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

GLYC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms